Biogen reported Phase 2 success for litifilimab, its anti-BDCA2 antibody in systemic lupus erythematosus, advancing the program toward what the company is targeting as a potential pillar of its immunology pipeline. In the 24-week readout, litifilimab improved skin lesions, with 14.7% of patients reaching the specified skin-lesion improvement endpoint. The update adds another data point to Biogen’s lupus strategy as it positions anti–type I interferon-pathway immunology assets for future regulatory and trial progression decisions.